Ionis Pharmaceuticals, Inc. (IONS)

$49.94

-0.06

(-0.12%)▲

Market is closed - opens 8 PM, 07 Dec 2023

Insights on Ionis Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 188.0M → 144.0M (in $), with an average decrease of 23.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -85.0M → -147.0M (in $), with an average decrease of 72.9% per quarter

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 80.8% return, outperforming this stock by 50.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 20.4% return, outperforming this stock by 21.1%

Performance

  • $49.72
    $50.43
    $49.94
    downward going graph

    0.44%

    Downside

    Day's Volatility :1.4%

    Upside

    0.96%

    downward going graph
  • $32.69
    $51.89
    $49.94
    downward going graph

    34.54%

    Downside

    52 Weeks Volatility :37.0%

    Upside

    3.76%

    downward going graph

Returns

PeriodIonis Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
23.68%
0.0%
0.0%
6 Months
23.16%
2.2%
0.0%
1 Year
30.73%
-4.7%
-2.1%
3 Years
-0.74%
18.0%
-6.5%

Highlights

Market Capitalization
7.4B
Book Value
$2.2
Dividend Share
0.0
Dividend Yield
3.07%
Earnings Per Share (EPS)
-2.87
PEG Ratio
25.7
Wall Street Target Price
53.29
Profit Margin
-66.57%
Operating Margin TTM
-99.35%
Return On Assets TTM
-12.92%
Return On Equity TTM
-90.01%
Revenue TTM
615.0M
Revenue Per Share TTM
4.31
Quarterly Revenue Growth YOY
-9.700000000000001%
Gross Profit TTM
-257.9M
EBITDA
-540.3M
Diluted Eps TTM
-2.87
Quarterly Earnings Growth YOY
-0.44
EPS Estimate Current Year
-3.43
EPS Estimate Next Year
-3.69
EPS Estimate Current Quarter
-1.07
EPS Estimate Next Quarter
-0.95

Analyst Recommendation

Buy
    60%Buy
    30%Hold
    10%Sell
Based on 30 Wall street analysts offering stock ratings for Ionis Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 30 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
17
Hold
9
7
7
Sell
3
4
4

Analyst Forecast

What analysts predicted

Upside of 6.71%

Current $49.94
Target $53.29

Company Financials

FY17Y/Y Change
Revenue
507.7M
↑ 46.46%
Net Income
-6.0M
↓ 93.1%
Net Profit Margin
-1.18%
↑ 23.79%
FY18Y/Y Change
Revenue
599.7M
↑ 18.12%
Net Income
273.7M
↓ 4685.28%
Net Profit Margin
45.65%
↑ 46.83%
FY19Y/Y Change
Revenue
1.1B
↑ 87.27%
Net Income
294.0M
↑ 7.4%
Net Profit Margin
26.18%
↓ 19.47%
FY20Y/Y Change
Revenue
729.0M
↓ 35.08%
Net Income
-487.0M
↓ 265.65%
Net Profit Margin
-66.8%
↓ 92.98%
FY21Y/Y Change
Revenue
810.0M
↑ 11.11%
Net Income
-29.0M
↓ 94.05%
Net Profit Margin
-3.58%
↑ 63.22%
FY22Y/Y Change
Revenue
587.0M
↓ 27.53%
Net Income
-270.0M
↑ 831.03%
Net Profit Margin
-46.0%
↓ 42.42%
Q2 FY22Q/Q Change
Revenue
133.8M
↓ 5.73%
Net Income
-105.1M
↑ 61.34%
Net Profit Margin
-78.58%
↓ 32.66%
Q3 FY22Q/Q Change
Revenue
159.8M
↑ 19.42%
Net Income
-47.0M
↓ 55.3%
Net Profit Margin
-29.41%
↑ 49.17%
Q4 FY22Q/Q Change
Revenue
152.0M
↓ 4.86%
Net Income
-52.0M
↑ 10.66%
Net Profit Margin
-34.21%
↓ 4.8%
Q1 FY23Q/Q Change
Revenue
131.0M
↓ 13.82%
Net Income
-124.0M
↑ 138.46%
Net Profit Margin
-94.66%
↓ 60.45%
Q2 FY23Q/Q Change
Revenue
188.0M
↑ 43.51%
Net Income
-85.0M
↓ 31.45%
Net Profit Margin
-45.21%
↑ 49.45%
Q3 FY23Q/Q Change
Revenue
144.0M
↓ 23.4%
Net Income
-147.0M
↑ 72.94%
Net Profit Margin
-102.08%
↓ 56.87%
FY17Y/Y Change
Total Assets
1.3B
↑ 44.88%
Total Liabilities
903.3M
↑ 11.12%
FY18Y/Y Change
Total Assets
2.7B
↑ 101.8%
Total Liabilities
1.5B
↑ 63.91%
FY19Y/Y Change
Total Assets
3.2B
↑ 21.19%
Total Liabilities
1.5B
↑ 4.55%
FY20Y/Y Change
Total Assets
2.4B
↓ 26.07%
Total Liabilities
1.5B
↓ 0.06%
FY21Y/Y Change
Total Assets
2.6B
↑ 9.29%
Total Liabilities
1.8B
↑ 18.94%
FY22Y/Y Change
Total Assets
2.5B
↓ 2.99%
Total Liabilities
2.0B
↑ 6.58%
Q2 FY22Q/Q Change
Total Assets
2.5B
↓ 2.5%
Total Liabilities
1.8B
↑ 1.21%
Q3 FY22Q/Q Change
Total Assets
2.4B
↓ 1.39%
Total Liabilities
1.8B
↓ 0.21%
Q4 FY22Q/Q Change
Total Assets
2.5B
↑ 4.63%
Total Liabilities
2.0B
↑ 7.3%
Q1 FY23Q/Q Change
Total Assets
2.9B
↑ 13.85%
Total Liabilities
2.4B
↑ 22.28%
Q2 FY23Q/Q Change
Total Assets
3.0B
↑ 2.98%
Total Liabilities
2.5B
↑ 6.05%
Q3 FY23Q/Q Change
Total Assets
2.9B
↓ 1.25%
Total Liabilities
2.6B
↑ 2.99%
FY17Y/Y Change
Operating Cash Flow
174.1M
↓ 255.34%
Investing Cash Flow
-358.3M
↓ 733.03%
Financing Cash Flow
229.1M
↑ 1910.59%
FY18Y/Y Change
Operating Cash Flow
602.9M
↑ 246.19%
Investing Cash Flow
-929.6M
↑ 159.44%
Financing Cash Flow
475.9M
↑ 107.72%
FY19Y/Y Change
Operating Cash Flow
345.7M
↓ 42.66%
Investing Cash Flow
-41.3M
↓ 95.56%
Financing Cash Flow
100.0M
↓ 78.98%
FY20Y/Y Change
Operating Cash Flow
35.9M
↓ 89.62%
Investing Cash Flow
274.5M
↓ 765.01%
Financing Cash Flow
-596.6M
↓ 696.48%
FY21Y/Y Change
Operating Cash Flow
30.8M
↓ 14.19%
Investing Cash Flow
194.9M
↓ 28.99%
Financing Cash Flow
245.9M
↓ 141.22%
FY22Y/Y Change
Operating Cash Flow
-274.4M
↓ 990.84%
Investing Cash Flow
-262.6M
↓ 234.75%
Financing Cash Flow
-55.3M
↓ 122.48%
Q2 FY22Q/Q Change
Operating Cash Flow
-18.1M
↓ 42.82%
Investing Cash Flow
-3.3M
↓ 98.85%
Financing Cash Flow
1.2M
↓ 116.59%
Q3 FY22Q/Q Change
Operating Cash Flow
-24.4M
↑ 35.0%
Investing Cash Flow
-183.9M
↑ 5466.89%
Financing Cash Flow
1.8M
↑ 50.95%
Q4 FY22Q/Q Change
Operating Cash Flow
-200.2M
↑ 719.5%
Investing Cash Flow
212.1M
↓ 215.34%
Financing Cash Flow
-51.0M
↓ 2881.84%
Q1 FY23Q/Q Change
Operating Cash Flow
-134.0M
↓ 33.07%
Investing Cash Flow
-325.6M
↓ 253.5%
Financing Cash Flow
492.1M
↓ 1064.52%
Q2 FY23Q/Q Change
Operating Cash Flow
-97.4M
↓ 27.34%
Investing Cash Flow
69.5M
↓ 121.35%
Financing Cash Flow
143.5M
↓ 70.83%

Technicals Summary

Sell

Neutral

Buy

Ionis Pharmaceuticals, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
4.67%
23.16%
30.73%
-0.74%
-5.99%
Moderna, Inc.
Moderna, Inc.
9.42%
-35.83%
-54.97%
-49.47%
333.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.6%
13.15%
9.35%
68.7%
124.16%
Novo Nordisk A/s
Novo Nordisk A/s
-4.03%
23.9%
55.84%
186.15%
330.1%
Seagen, Inc.
Seagen, Inc.
0.86%
10.81%
80.8%
20.4%
259.73%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.55%
8.87%
11.3%
55.67%
105.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
524.14
NA
25.7
-3.43
-0.9
-0.13
0.03
2.2
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.72
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
23.18
23.18
1.75
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.18
41.18
4.02
2.67
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.38
26.38
0.5
15.04
0.23
0.14
0.0
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Buy
$7.4B
-5.99%
524.14
-66.57%
Moderna, Inc.
Moderna, Inc.
Buy
$30.4B
333.33%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.5B
124.16%
23.18
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$459.0B
330.1%
41.18
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.2B
259.73%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.5B
105.25%
26.38
35.94%

Institutional Holdings

  • FMR Inc

    14.96%

  • Vanguard Group Inc

    10.11%

  • T. Rowe Price Investment Management,Inc.

    9.15%

  • Bellevue Group AG

    6.54%

  • BlackRock Inc

    6.37%

  • ClearBridge Advisors, LLC

    3.37%

Company Information

ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.

Organization
Ionis Pharmaceuticals, Inc.
Employees
796
CEO
Dr. Brett P. Monia Ph.D.
Industry
Health Technology

Discover More

FAQs